The Valley Desk

NCT03760081 · Interventional trial

A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors

Overall registry status Completed

Phase 2

Conditions Incurable Platinum Refractory Germ Cell Tumors, Tumors

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov